Articles tagged with: Drugs

Our ovarian cancer research

Posted in General News Published by Bethan Warman 13 March 2019

Ovarian Cancer Awareness Month

Our ovarian cancer research

This month is Ovarian Cancer Awareness Month. In the UK each year, around 7,300 women are diagnosed with ovarian cancer, making it the sixth most common cancer type in females. Here at the Barts Cancer Institute, our researchers are working to better understand the biology of ovarian cancer and translate this knowledge into new diagnostic and treatment strategies. One particular focus of our ovarian cancer research is understanding and combating the development of resistance to therapy, which is a major obstacle in the successful treatment of many cancer types.

Combination therapy improves survival in advanced kidney cancer

Posted in General News Published by Bethan Warman 13 February 2019

Combination therapy improves survival in advanced kidney cancer

A combination therapy has shown powerful anticancer responses in patients with a type of advanced kidney cancer in a new international phase III clinical trial (KEYNOTE-426). Treatment with the combination therapy resulted in significant increases in overall survival when compared with the current standard of care, and the findings will help to provide a vital new treatment option for patients with this disease.

Tackling tumour scar tissue could be key to treating pancreatic cancer

Posted in General News, Publications Published by Administrator 11 February 2019

Tackling tumour scar tissue could be key to treating pancreatic cancer

The first study in the world to take a detailed look at scar tissue in human pancreatic cancer has revealed a range of different scar tissue types that could help clinicians predict which patients will respond best to particular treatments.

Immune cells found as accomplices in melanoma spread

Posted in General News, Publications Published by Bethan Warman 31 January 2019

Immune cells found as accomplices in melanoma spread

A new study published today in Cell has revealed that aggressive melanoma cells are able to manipulate the immune system to their advantage. As a result, immune cells that are supposed to recognise and destroy cancer cells actually behave differently and support the growth and spread of the tumour.

BCI at the 60th ASH Annual Meeting

Posted in General News, BCI on the Road Published by Bethan Warman 14 January 2019

‘The premier event in malignant and non-malignant haematology’

BCI at the 60th ASH Annual Meeting

Researchers from our Centre for Haemato-Oncology attended the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego on 1st-4th December 2018. The ASH Annual Meeting provides an invaluable opportunity to showcase the work being conducted here at the BCI and brings together professionals from all subspecialties of blood disease research.

Tackling the deadliest cancer type

Posted in General News Published by Bethan Warman 30 November 2018

Our lung cancer research

Tackling the deadliest cancer type

This month is Lung Cancer Awareness Month. Lung cancer is the third most common cancer in the UK, with 46,700 new cases diagnosed each year. Approximately 35,600 people lose their lives annually as a result of lung cancer in the UK, making it the most common cause of cancer-related mortality. Only 5% of those affected survive their cancer for 10 years or more in the UK, and this survival rate has not shown much improvement over the last four decades.

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

Posted in General News, BCI on the Road, Publications Published by Bethan Warman 22 October 2018

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

New research led by Barts Cancer Institute and St Bartholomew’s Hospital has provided new hope for people with an aggressive type of breast cancer. The phase 3 clinical trial has shown that by using a combination of immunotherapy and chemotherapy, the body’s own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Posted in General News, Publications Published by Bethan Warman 17 October 2018

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC). The phase 1 clinical trial, led by Prof Peter Schmid, Centre Lead for BCI’s Centre for Experimental Cancer Medicine, is the first to report the long-term safety and efficacy of the drug for mTNBC, and may represent significant steps forward for treatment of this disease.

Blood Cancer Awareness Month 2018

Posted in General News Published by Bethan Warman 28 September 2018

Blood Cancer Awareness Month 2018

Blood Cancer Awareness Month takes place every September to raise awareness of the challenges faced by those living with blood cancer. In the UK, blood cancer is the fifth most common cancer, with 240,000 people living with the disease and 38,000 people being diagnosed with a type of blood cancer each year. The three main blood cancer types are leukaemia, lymphoma and myeloma; however, there are over 100 individual types.

World Cancer Research Day 2018

Posted in General News Published by Bethan Warman 24 September 2018

World Cancer Research Day 2018

Today is World Cancer Research Day- a day dedicated to raising awareness of the importance of cancer research. Thanks to a united effort by researchers from around the world, cancer survival rates have doubled in the last 40 years, and 50% of those diagnosed with cancer now survive. To continue to improve these statistics, it is vital to identify new and more effective early detection methods and treatments that can improve the lives of those with cancer.

[12  >>  
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.